XML 48 R26.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment and Geographic Information (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Reporting Segments | Segment and Geographic Information The structure of our internal organization is divided into the following reportable segments, which are also our operating segments: E&C, D&S, and BioMedical. Our reportable segments are business units that are each managed separately because they manufacture, offer, and distribute distinct products with different production processes. The E&C and D&S segments manufacture products used primarily in energy-related and industrial applications, such as the separation, liquefaction, distribution, and storage of hydrocarbon and industrial gases. The BioMedical segment supplies cryogenic and other equipment used in the medical, biological research, and animal breeding industries. Intersegment sales are not material. Corporate includes operating expenses for executive management, accounting, tax, treasury, corporate development, human resources, information technology, investor relations, legal, internal audit, and risk management. Corporate support functions are not currently allocated to the segments. We evaluate performance and allocates resources based on operating income or loss from continuing operations before interest expense, net, loss on extinguishment of debt, financing costs amortization, foreign currency loss (gain), income tax (benefit) expense, net, and income (loss) attributable to noncontrolling interests, net of taxes. The accounting policies of the reportable segments are the same as those described in Note 2. Segment Financial Information
| Year Ended December 31, 2017
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Corporate |  | Total
Sales to external customers | $ | 225.6 |  |  | $ | 540.3 |  |  | $ | 222.9 |  |  | $ | — |  |  | $ | 988.8 |
Depreciation and amortization expense | 15.3 |  |  | 18.8 |  |  | 5.6 |  |  | 2.2 |  |  | 41.9 |
Operating income (loss) (1) (2) | 5.1 |  |  | 66.1 |  |  | 35.5 |  |  | (64.7 | ) |  | 42.0 |
Total assets | 782.9 |  |  | 685.2 |  |  | 165.9 |  |  | 90.7 |  |  | 1,724.7 |
Capital expenditures | 15.5 |  |  | 14.4 |  |  | 3.0 |  |  | 2.3 |  |  | 35.2 |
| Year Ended December 31, 2016
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Corporate |  | Total
Sales to external customers | $ | 154.3 |  |  | $ | 497.1 |  |  | $ | 207.8 |  |  | $ | — |  |  | $ | 859.2 |
Depreciation and amortization expense | 10.0 |  |  | 18.4 |  |  | 6.0 |  |  | 3.1 |  |  | 37.5 |
Operating income (loss) (1) (3) | 13.3 |  |  | 50.4 |  |  | 42.0 |  |  | (48.3 | ) |  | 57.4 |
Total assets | 177.5 |  |  | 657.6 |  |  | 178.7 |  |  | 219.2 |  |  | 1,233.0 |
Capital expenditures | 3.3 |  |  | 11.7 |  |  | 2.3 |  |  | 0.5 |  |  | 17.8 |
| Year Ended December 31, 2015
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Corporate |  | Total
Sales to external customers | $ | 331.0 |  |  | $ | 487.6 |  |  | $ | 221.6 |  |  | $ | — |  |  | $ | 1,040.2 |
Depreciation and amortization expense | 11.8 |  |  | 18.3 |  |  | 12.0 |  |  | 3.3 |  |  | 45.4 |
Operating (loss) income (1) (4) | (10.0 | ) |  | 39.5 |  |  | (165.3 | ) |  | (47.4 | ) |  | (183.2 | )
Total assets | 251.8 |  |  | 689.1 |  |  | 224.4 |  |  | 34.8 |  |  | 1,200.1 |
Capital expenditures | 4.1 |  |  | 36.8 |  |  | 3.9 |  |  | 2.3 |  |  | 47.1 |
_______________
(1) | Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively.
(2) | Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.
(3) | During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.
(4) | Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.
Product Sales Information
| Year Ended December 31,
| 2017 |  | 2016 |  | 2015
Energy & Chemicals |  |  |  |  |
Natural gas processing (including petrochemical) applications | $ | 152.9 |  |  | $ | 105.4 |  |  | $ | 180.9 |
Liquefied natural gas applications | 29.5 |  |  | 38.2 |  |  | 136.1 |
Industrial gas applications | 22.4 |  |  | 10.7 |  |  | 14.0 |
HVAC, power and refining | 20.8 |  |  | — |  |  | — |
Total Energy & Chemicals | 225.6 |  |  | 154.3 |  |  | 331.0 |
Distribution & Storage |  |  |  |  |
Bulk industrial gas applications | 221.9 |  |  | 227.6 |  |  | 203.9 |
Packaged gas industrial applications | 180.7 |  |  | 159.7 |  |  | 167.8 |
Liquefied natural gas applications | 137.7 |  |  | 109.8 |  |  | 115.9 |
Total Distribution & Storage | 540.3 |  |  | 497.1 |  |  | 487.6 |
BioMedical |  |  |  |  |
Respiratory therapy | 124.4 |  |  | 118.9 |  |  | 132.3 |
Cryobiological storage | 77.0 |  |  | 70.6 |  |  | 64.6 |
On-site generation systems | 21.5 |  |  | 18.3 |  |  | 24.7 |
Total BioMedical | 222.9 |  |  | 207.8 |  |  | 221.6 |
Total | $ | 988.8 |  |  | $ | 859.2 |  |  | $ | 1,040.2 |
In 2017 and 2015, no one customer accounted for more than 10% of our consolidated sales. In 2016, one customer, Airgas “an Air Liquide company” and Air Liquide, accounted for more than 10% of our consolidated sales. Total sales from this customer represented approximately $98.9 of our 2016 consolidated sales and is attributable to our E&C, D&S and BioMedical segments. Geographic Information Net sales by geographic area are reported by the destination of sales. Net property, plant and equipment by geographic area are reported by country of domicile.
| Sales for the Year Ended December 31,
| 2017 |  | 2016 |  | 2015
United States | $ | 526.7 |  |  | $ | 426.0 |  |  | $ | 513.7 |
Foreign |  |  |  |  |
China | 110.0 |  |  | 147.7 |  |  | 110.0 |
Other foreign countries | 352.1 |  |  | 285.5 |  |  | 416.5 |
Total Foreign | 462.1 |  |  | 433.2 |  |  | 526.5 |
Total | $ | 988.8 |  |  | $ | 859.2 |  |  | $ | 1,040.2 |
| Property, plant and equipment, net as of December 31,
| 2017 |  | 2016
United States | $ | 177.9 |  |  | $ | 145.0 |
Foreign |  |  |
China | 82.9 |  |  | 75.4 |
Czech Republic | 20.7 |  |  | 18.5 |
Germany | 13.4 |  |  | 11.5 |
Other foreign countries | 2.7 |  |  | 0.6 |
Total Foreign | 119.7 |  |  | 106.0 |
Total | $ | 297.6 |  |  | $ | 251.0 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration